Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11/2010

01-11-2010 | Original Article

Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load

Authors: Wei Dong, Jiajun Du, Hongchang Shen, Dongwei Gao, Zhenxiang Li, Guanghui Wang, Xueru Mu, Qi Liu

Published in: Cancer Immunology, Immunotherapy | Issue 11/2010

Login to get access

Abstract

The history of immunizing animals with fetal tissues to generate an antitumor response dates back a century ago. Subsequent reports supported the idea that vaccination with embryonic materials could generate cancer-specific immunity and protect animals from transplantable and chemically induced tumors. In our study, we found C57 BL/6 mice vaccinated with embryonic stem cells (ESCs) received obvious antitumor immunity, which protected them from the formation and development of lung cancer. Furthermore, we investigated the antitumor effects of administration of ESCs in mice with minor and/or heavy tumor load. The tumor growth was monitored, the proliferation of lymphocytes and secretion of cytokines were examined, and finally the tissue sections were approached by immunohistochemical and apoptosis staining. The results suggested that mice injected with ESCs received obvious tumor inhibition and retardation due to significant lymphocyte proliferation and cytokine secretion, which help to rebuild the host’s immunity against cancer to some extent and comprise the main part of antitumor immunity. Moreover, mice with minor tumor load received stronger antitumor effect compared with mice with heavy tumor load, may be due to relatively intact immune system. Thus, besides their function as prophylactic vaccines, administration of ESCs could be a potential treatment for cancer, which obviously prevent and control the proliferation and development of malignant tumors.
Literature
1.
go back to reference Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111CrossRefPubMed Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111CrossRefPubMed
2.
go back to reference Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMed Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988CrossRefPubMed
3.
go back to reference Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMed Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401CrossRefPubMed
4.
go back to reference Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037CrossRefPubMed Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037CrossRefPubMed
5.
go back to reference O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110CrossRefPubMed O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110CrossRefPubMed
6.
go back to reference Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480–1485CrossRefPubMed Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci USA 103:1480–1485CrossRefPubMed
7.
go back to reference Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967–976CrossRefPubMed Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967–976CrossRefPubMed
8.
go back to reference Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973–978CrossRefPubMed Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973–978CrossRefPubMed
9.
go back to reference Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3:895–902CrossRefPubMed Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3:895–902CrossRefPubMed
10.
go back to reference Cabanillas R, Llorente JL (2009) The Stem Cell Network model: clinical implications in cancer. Eur Arch Otorhinolaryngol 266:161–170CrossRefPubMed Cabanillas R, Llorente JL (2009) The Stem Cell Network model: clinical implications in cancer. Eur Arch Otorhinolaryngol 266:161–170CrossRefPubMed
12.
go back to reference Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557CrossRefPubMed Li L, Neaves WB (2006) Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553–4557CrossRefPubMed
13.
go back to reference Huang EH, Heidt DG, Li CW, Simeone DM (2007) Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141:415–419CrossRefPubMed Huang EH, Heidt DG, Li CW, Simeone DM (2007) Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141:415–419CrossRefPubMed
14.
go back to reference Okamoto OK (2009) Cancer stem cell genomics: the quest for early markers of malignant progression. Expert Rev Mol Diagn 9:545–554CrossRefPubMed Okamoto OK (2009) Cancer stem cell genomics: the quest for early markers of malignant progression. Expert Rev Mol Diagn 9:545–554CrossRefPubMed
15.
go back to reference Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A (2005) Spontaneous human adult stem cell transformation. Cancer Res 65:3035–3039PubMed Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A (2005) Spontaneous human adult stem cell transformation. Cancer Res 65:3035–3039PubMed
16.
go back to reference Li Y, Zeng H, Xu RH, Liu B, Li Z (2009) Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 27:3103–3111PubMed Li Y, Zeng H, Xu RH, Liu B, Li Z (2009) Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 27:3103–3111PubMed
17.
go back to reference Brewer BG, Mitchell RA, Harandi A, Eaton JW (2009) Embryonic vaccines against cancer: an early history. Exp Mol Pathol 86:192–197CrossRefPubMed Brewer BG, Mitchell RA, Harandi A, Eaton JW (2009) Embryonic vaccines against cancer: an early history. Exp Mol Pathol 86:192–197CrossRefPubMed
18.
go back to reference LeMevel BP, Wells SA Jr (1973) Foetal antigens cross-reactive with tumour-specific transplantation antigens. Nat New Biol 244:183–184CrossRefPubMed LeMevel BP, Wells SA Jr (1973) Foetal antigens cross-reactive with tumour-specific transplantation antigens. Nat New Biol 244:183–184CrossRefPubMed
19.
go back to reference Sikora K, Stern P, Lennox E (1977) Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature 269:813–815CrossRefPubMed Sikora K, Stern P, Lennox E (1977) Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature 269:813–815CrossRefPubMed
20.
go back to reference Coggin JH Jr, Adkinson L, Anderson NG (1980) Fetal antigens shared as transplantation rejection antigens on chemically induced mouse and hamster sarcomas. Cancer Res 40:1568–1573PubMed Coggin JH Jr, Adkinson L, Anderson NG (1980) Fetal antigens shared as transplantation rejection antigens on chemically induced mouse and hamster sarcomas. Cancer Res 40:1568–1573PubMed
21.
go back to reference Bertram JS, Janik P (1980) Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett 11:63–73CrossRefPubMed Bertram JS, Janik P (1980) Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett 11:63–73CrossRefPubMed
22.
go back to reference Wang Z, Tang X, Li Y, Leu C, Guo L, Zheng X, Zhu D (2008) 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol 588:9–17CrossRefPubMed Wang Z, Tang X, Li Y, Leu C, Guo L, Zheng X, Zhu D (2008) 20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. Eur J Pharmacol 588:9–17CrossRefPubMed
23.
go back to reference Rosato A, Zoso A, Dalla Santa S, Milan G, Del Bianco P, De Salvo GL, Zanovello P (2006) Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. J Immunol 176:1999–2006PubMed Rosato A, Zoso A, Dalla Santa S, Milan G, Del Bianco P, De Salvo GL, Zanovello P (2006) Predicting tumor outcome following cancer vaccination by monitoring quantitative and qualitative CD8+ T cell parameters. J Immunol 176:1999–2006PubMed
24.
go back to reference van Herck H, Baumans V, Brandt CJ, Hesp AP, Sturkenboom JH, van Lith HA, van Tintelen G, Beynen AC (1998) Orbital sinus blood sampling in rats as performed by different animal technicians: the influence of technique and expertise. Lab Anim 32:377–386CrossRefPubMed van Herck H, Baumans V, Brandt CJ, Hesp AP, Sturkenboom JH, van Lith HA, van Tintelen G, Beynen AC (1998) Orbital sinus blood sampling in rats as performed by different animal technicians: the influence of technique and expertise. Lab Anim 32:377–386CrossRefPubMed
25.
go back to reference Mayo JG (1972) Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 23:325–330 Mayo JG (1972) Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 23:325–330
26.
go back to reference Jaffee EM (2006) Immunotherapy of Cancer. Ann NY Acad Sci 67–72 Jaffee EM (2006) Immunotherapy of Cancer. Ann NY Acad Sci 67–72
27.
go back to reference Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43–47CrossRefPubMed Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43–47CrossRefPubMed
28.
go back to reference Jordan CT (2005) Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2:224–225CrossRefPubMed Jordan CT (2005) Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biology. Nat Clin Pract Oncol 2:224–225CrossRefPubMed
29.
go back to reference Copland M, Fraser AR, Harrison SJ, Holyoake TL (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol Immunother 54:297–306CrossRefPubMed Copland M, Fraser AR, Harrison SJ, Holyoake TL (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunol Immunother 54:297–306CrossRefPubMed
30.
31.
go back to reference Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15CrossRefPubMed Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15CrossRefPubMed
32.
go back to reference Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70:516–525CrossRefPubMed Sioud M (2009) Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand J Immunol 70:516–525CrossRefPubMed
33.
go back to reference Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, Jackel D, Hensel M, Metelitsa LS. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 126:2622–2634 Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, Jackel D, Hensel M, Metelitsa LS. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer 126:2622–2634
34.
go back to reference Johnsen A, France J, Sy MS, Harding CV (1998) Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 58:3660–3667PubMed Johnsen A, France J, Sy MS, Harding CV (1998) Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res 58:3660–3667PubMed
35.
go back to reference Drukker M, Katchman H, Katz G, Even-Tov Friedman S, Shezen E, Hornstein E, Mandelboim O, Reisner Y, Benvenisty N (2006) Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24:221–229CrossRefPubMed Drukker M, Katchman H, Katz G, Even-Tov Friedman S, Shezen E, Hornstein E, Mandelboim O, Reisner Y, Benvenisty N (2006) Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24:221–229CrossRefPubMed
36.
go back to reference Drukker M, Benvenisty N (2004) The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 22:136–141CrossRefPubMed Drukker M, Benvenisty N (2004) The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol 22:136–141CrossRefPubMed
37.
go back to reference Fairchild PJ, Cartland S, Nolan KF, Waldmann H (2004) Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol 25:465–470CrossRefPubMed Fairchild PJ, Cartland S, Nolan KF, Waldmann H (2004) Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol 25:465–470CrossRefPubMed
38.
go back to reference Boyd AS, Higashi Y, Wood KJ (2005) Transplanting stem cells: potential targets for immune attack. Modulating the immune response against embryonic stem cell transplantation. Adv Drug Deliv Rev 57:1944–1969CrossRefPubMed Boyd AS, Higashi Y, Wood KJ (2005) Transplanting stem cells: potential targets for immune attack. Modulating the immune response against embryonic stem cell transplantation. Adv Drug Deliv Rev 57:1944–1969CrossRefPubMed
39.
go back to reference Begley J, Ribas A (2008) Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 14:4385–4391CrossRefPubMed Begley J, Ribas A (2008) Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 14:4385–4391CrossRefPubMed
40.
go back to reference Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915CrossRefPubMed Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915CrossRefPubMed
41.
go back to reference Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697–703CrossRefPubMed Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697–703CrossRefPubMed
42.
go back to reference Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21:339–359CrossRefPubMed Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21:339–359CrossRefPubMed
43.
go back to reference Koestenbauer S, Zech NH, Juch H, Vanderzwalmen P, Schoonjans L, Dohr G (2006) Embryonic stem cells: similarities and differences between human and murine embryonic stem cells. Am J Reprod Immunol 55:169–180CrossRefPubMed Koestenbauer S, Zech NH, Juch H, Vanderzwalmen P, Schoonjans L, Dohr G (2006) Embryonic stem cells: similarities and differences between human and murine embryonic stem cells. Am J Reprod Immunol 55:169–180CrossRefPubMed
Metadata
Title
Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load
Authors
Wei Dong
Jiajun Du
Hongchang Shen
Dongwei Gao
Zhenxiang Li
Guanghui Wang
Xueru Mu
Qi Liu
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0899-9

Other articles of this Issue 11/2010

Cancer Immunology, Immunotherapy 11/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine